{"component": "definition", "props": {"groups": [{"snippet": "means any data included in the CMC portion of a Regulatory Filing or in any supporting development reports thereto, in each case, with respect to any Licensed Product in any country in the world.", "size": 18, "snippet_links": [{"key": "regulatory-filing", "type": "clause", "offset": [48, 65]}, {"key": "development-reports", "type": "clause", "offset": [87, 106]}, {"key": "each-case", "type": "definition", "offset": [119, 128]}, {"key": "with-respect-to", "type": "clause", "offset": [130, 145]}, {"key": "licensed-product", "type": "definition", "offset": [150, 166]}, {"key": "the-world", "type": "definition", "offset": [185, 194]}], "samples": [{"hash": "iWX7FNj2A6l", "uri": "/contracts/iWX7FNj2A6l#cmc-data", "label": "License and Collaboration Agreement (LianBio)", "score": 34.2347717285, "published": true}, {"hash": "dqx1nA5AtKY", "uri": "/contracts/dqx1nA5AtKY#cmc-data", "label": "License and Collaboration Agreement (Landos Biopharma, Inc.)", "score": 32.57289505, "published": true}, {"hash": "lTdtVvpKZlf", "uri": "/contracts/lTdtVvpKZlf#cmc-data", "label": "Exclusive License Agreement (LianBio)", "score": 32.4880218506, "published": true}], "hash": "c1d5ebbe3b62eeee5ad75e2141ade7ab", "id": 1}, {"snippet": "means the chemistry, manufacturing and controls data for each Research Product, product Directed to a ROFN Target, Licensed Compound or Licensed Product, as applicable, required by Applicable Law to be included or referenced in, or that otherwise supports, an application for Regulatory Approval.", "size": 17, "snippet_links": [{"key": "research-product", "type": "definition", "offset": [62, 78]}, {"key": "directed-to", "type": "definition", "offset": [88, 99]}, {"key": "rofn-target", "type": "definition", "offset": [102, 113]}, {"key": "licensed-compound", "type": "definition", "offset": [115, 132]}, {"key": "licensed-product", "type": "definition", "offset": [136, 152]}, {"key": "required-by", "type": "definition", "offset": [169, 180]}, {"key": "applicable-law", "type": "definition", "offset": [181, 195]}, {"key": "application-for-regulatory-approval", "type": "clause", "offset": [260, 295]}], "samples": [{"hash": "4e31ZswAVqX", "uri": "/contracts/4e31ZswAVqX#cmc-data", "label": "Collaboration and Option Agreement (Morphic Holding, Inc.)", "score": 30.4757022858, "published": true}, {"hash": "1Ch051ZTnrc", "uri": "/contracts/1Ch051ZTnrc#cmc-data", "label": "Collaboration and Option Agreement (Morphic Holding, Inc.)", "score": 30.4483222961, "published": true}, {"hash": "8kH8hp752hB", "uri": "/contracts/8kH8hp752hB#cmc-data", "label": "Collaboration and Option Agreement (Morphic Holding, Inc.)", "score": 30.4072551727, "published": true}], "hash": "63336c354d0dbdc7a8c575a29c51ee4c", "id": 2}, {"snippet": "means any and all information contained in, as well as data supporting, the Chemistry, Manufacturing and Control section of an IND or NDA for the Product, and any similar information or data required with respect to any other Regulatory Approval.", "size": 14, "snippet_links": [{"key": "all-information", "type": "clause", "offset": [14, 29]}, {"key": "contained-in", "type": "definition", "offset": [30, 42]}, {"key": "the-product", "type": "clause", "offset": [142, 153]}, {"key": "data-required", "type": "clause", "offset": [186, 199]}, {"key": "with-respect-to", "type": "clause", "offset": [200, 215]}, {"key": "regulatory-approval", "type": "definition", "offset": [226, 245]}], "samples": [{"hash": "4uqPe6mxh0k", "uri": "/contracts/4uqPe6mxh0k#cmc-data", "label": "Feasibility, Development and Commercialization Agreement (Auto Search Cars, Inc.)", "score": 21.470911026, "published": true}, {"hash": "87sElADY7D7", "uri": "/contracts/87sElADY7D7#cmc-data", "label": "Feasibility, Development and Commercialization Agreement (Auto Search Cars, Inc.)", "score": 21.3997268677, "published": true}, {"hash": "eyAyRL64ayA", "uri": "/contracts/eyAyRL64ayA#cmc-data", "label": "Feasibility, Development and Commercialization Agreement (Auto Search Cars, Inc.)", "score": 21.3175907135, "published": true}], "hash": "98beb8df6ee6ccd7baed329c91b00a5b", "id": 3}, {"snippet": "means the chemistry, manufacturing and controls data required by Applicable Law to be included in a New Drug Application (as defined in the FFDCA and the regulations promulgated thereunder) for a Product or in any other Marketing Authorization outside the United States.", "size": 10, "snippet_links": [{"key": "required-by", "type": "definition", "offset": [53, 64]}, {"key": "applicable-law", "type": "definition", "offset": [65, 79]}, {"key": "new-drug-application", "type": "definition", "offset": [100, 120]}, {"key": "the-regulations", "type": "clause", "offset": [150, 165]}, {"key": "marketing-authorization", "type": "definition", "offset": [220, 243]}, {"key": "outside-the-united-states", "type": "clause", "offset": [244, 269]}], "samples": [{"hash": "jUDfo2MwbGp", "uri": "/contracts/jUDfo2MwbGp#cmc-data", "label": "Manufacturing and Supply Agreement", "score": 31.3408622742, "published": true}, {"hash": "fJwzsIdd1fY", "uri": "/contracts/fJwzsIdd1fY#cmc-data", "label": "Manufacturing Agreement (Salix Pharmaceuticals LTD)", "score": 22.8535251617, "published": true}, {"hash": "g6PjwK0iNyr", "uri": "/contracts/g6PjwK0iNyr#cmc-data", "label": "Manufacturing Agreement (Salix Pharmaceuticals LTD)", "score": 21.0, "published": true}], "hash": "5c8c5fe80c1042f5fa8fe21d7642c3d2", "id": 4}, {"snippet": "means CMC data, results and reports that are generated with respect to the Product or the Durect Technology to the extent incorporated into or utilized in the Product, and that are Controlled at any time during the Term of this Agreement by a Party, or any Affiliate, subcontractor, agent, sublicensee thereof, or jointly by any of the foregoing.", "size": 7, "snippet_links": [{"key": "results-and-reports", "type": "clause", "offset": [16, 35]}, {"key": "with-respect-to", "type": "clause", "offset": [55, 70]}, {"key": "the-product", "type": "clause", "offset": [71, 82]}, {"key": "durect-technology", "type": "definition", "offset": [90, 107]}, {"key": "to-the-extent", "type": "clause", "offset": [108, 121]}, {"key": "at-any-time", "type": "clause", "offset": [192, 203]}, {"key": "during-the-term-of-this-agreement", "type": "clause", "offset": [204, 237]}, {"key": "by-a-party", "type": "clause", "offset": [238, 248]}, {"key": "the-foregoing", "type": "definition", "offset": [332, 345]}], "samples": [{"hash": "aspdC4LcIUX", "uri": "/contracts/aspdC4LcIUX#cmc-data", "label": "Development and License Agreement (Zogenix, Inc.)", "score": 22.6098556519, "published": true}, {"hash": "1SlnrqjJApq", "uri": "/contracts/1SlnrqjJApq#cmc-data", "label": "Development and License Agreement (Durect Corp)", "score": 21.8480491638, "published": true}, {"hash": "jKggptJicYK", "uri": "https://investors.durect.com/static-files/e3c72452-4ac6-44fc-8dac-e71c34831024", "label": "investors.durect.com", "score": 7.740588665, "published": false}], "hash": "dd0a7f7a88841c9d91bcd8d0eb536cd2", "id": 5}, {"snippet": "means the chemistry, manufacturing and controls data required by Applicable Law to be included in a BLA or NDA for a Licensed Product.", "size": 6, "snippet_links": [{"key": "required-by", "type": "definition", "offset": [53, 64]}, {"key": "applicable-law", "type": "definition", "offset": [65, 79]}, {"key": "licensed-product", "type": "definition", "offset": [117, 133]}], "samples": [{"hash": "eWSPSzwkg3J", "uri": "/contracts/eWSPSzwkg3J#cmc-data", "label": "License Agreement", "score": 31.3408622742, "published": true}, {"hash": "f7YrvOj8NCi", "uri": "/contracts/f7YrvOj8NCi#cmc-data", "label": "License Agreement (Immune Design Corp.)", "score": 28.3347015381, "published": true}], "hash": "eba71a0b9f0c6848a9339d244dc00f60", "id": 6}, {"snippet": "means the data contained in the chemistry, manufacturing and controls section of a submission for Regulatory Approval of the Product in the Field in the Territory.", "size": 5, "snippet_links": [{"key": "the-data", "type": "clause", "offset": [6, 14]}, {"key": "contained-in", "type": "definition", "offset": [15, 27]}, {"key": "approval-of-the-product", "type": "clause", "offset": [109, 132]}, {"key": "in-the-field", "type": "clause", "offset": [133, 145]}, {"key": "in-the-territory", "type": "clause", "offset": [146, 162]}], "samples": [{"hash": "ffApXQraajB", "uri": "/contracts/ffApXQraajB#cmc-data", "label": "License, Development, Commercialization and Supply Agreement (Sucampo Pharmaceuticals, Inc.)", "score": 26.5906906128, "published": true}, {"hash": "cRoipUp5zOT", "uri": "/contracts/cRoipUp5zOT#cmc-data", "label": "License Agreement (Sucampo Pharmaceuticals, Inc.)", "score": 21.0, "published": true}, {"hash": "hIvKMkKEkll", "uri": "https://mallinckrodt.gcs-web.com/static-files/89c75b67-3169-46ba-a6c5-cddfb50e4396", "label": "mallinckrodt.gcs-web.com", "score": 7.6954140663, "published": false}], "hash": "4e2b5c0d1dbfd2a28f311059c609012b", "id": 7}, {"snippet": "means those data required by Part 2 of the Annex to Directive 2001/83/EC including the qualitative and quantitative particulars of the constituents, the description of the manufacturing method and the controls and tests carried out at all relevant stages of the manufacturing process.", "size": 4, "snippet_links": [{"key": "required-by", "type": "definition", "offset": [17, 28]}, {"key": "part-2", "type": "definition", "offset": [29, 35]}, {"key": "directive-2001-83", "type": "definition", "offset": [52, 69]}, {"key": "description-of-the", "type": "definition", "offset": [153, 171]}, {"key": "manufacturing-process", "type": "definition", "offset": [262, 283]}], "samples": [{"hash": "kExDPlbOnt2", "uri": "/contracts/kExDPlbOnt2#cmc-data", "label": "Distribution and License Agreement (NPS Pharmaceuticals Inc)", "score": 21.0, "published": true}], "hash": "43ac99fe310dc72c7e80dd7d9dc19749", "id": 8}, {"snippet": "means all chemistry, manufacturing and controls information related to Clinical Material, ITO or Product that is required to be included in Equillium\u2019s Regulatory Filings for such Product.", "size": 3, "snippet_links": [{"key": "related-to", "type": "clause", "offset": [60, 70]}, {"key": "clinical-material", "type": "definition", "offset": [71, 88]}, {"key": "regulatory-filings", "type": "clause", "offset": [152, 170]}], "samples": [{"hash": "eglvwfckJT6", "uri": "/contracts/eglvwfckJT6#cmc-data", "label": "Clinical Supply Agreement (Equillium, Inc.)", "score": 34.6016426086, "published": true}, {"hash": "9HZzblecC9U", "uri": "/contracts/9HZzblecC9U#cmc-data", "label": "Clinical Supply Agreement", "score": 31.3408622742, "published": true}, {"hash": "fqUstYTqxpR", "uri": "/contracts/fqUstYTqxpR#cmc-data", "label": "Clinical Supply Agreement (Equillium, Inc.)", "score": 29.585899353, "published": true}], "hash": "48d6da6bbd6b84d5645ae075695eef5a", "id": 9}, {"snippet": "means any and all Information contained in, as well as data supporting, the Chemistry, Manufacturing and Control sections (or sections corresponding thereto) of an NDA, or other equivalent regulatory filing, relating to the Product.", "size": 3, "snippet_links": [{"key": "all-information", "type": "clause", "offset": [14, 29]}, {"key": "contained-in", "type": "definition", "offset": [30, 42]}, {"key": "regulatory-filing", "type": "clause", "offset": [189, 206]}, {"key": "relating-to", "type": "definition", "offset": [208, 219]}, {"key": "the-product", "type": "clause", "offset": [220, 231]}], "samples": [{"hash": "g0Hy5DrdhSB", "uri": "/contracts/g0Hy5DrdhSB#cmc-data", "label": "Co Development, License and Co Promotion Agreement (Nektar Therapeutics)", "score": 22.1608486176, "published": true}, {"hash": "ai1Kox8T6Jv", "uri": "/contracts/ai1Kox8T6Jv#cmc-data", "label": "Co Development, License and Co Promotion Agreement (Nektar Therapeutics)", "score": 21.0, "published": true}, {"hash": "cdwZP7dKN1S", "uri": "https://ir.nektar.com/static-files/e8e2cf31-08e1-4fcc-86e9-fb7c61e755d9", "label": "ir.nektar.com", "score": 14.7575540543, "published": false}], "hash": "dbc97a7746856524d9a2be7f974a9e97", "id": 10}], "next_curs": "ClUST2oVc35sYXdpbnNpZGVyY29udHJhY3RzcjELEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIRY21jLWRhdGEjMDAwMDAwMGEMogECZW4YACAA", "definition": {"snippet": "means any data included in the CMC portion of a Regulatory Filing or in any supporting development reports thereto, in each case, with respect to any Licensed Product in any country in the world.", "size": 118, "title": "CMC Data", "id": "cmc-data", "examples": ["For clarity, <strong>CMC Data</strong> included in such submissions shall be subject to Section 7.3.b.", "Under the Second Indication Development Plan and other future development plans for Additional Indications activities will primarily be managed and conducted by Otsuka at its own cost and expense save that GW Pharma shall be responsible for the generation of all relevant <strong>CMC Data</strong> at its own cost and expense.", "The budget set forth in the First Indication Development Plan (the \u201cDevelopment Budget\u201d) shall set out the Third Party costs projected to be incurred by GW Pharma in the performance of its obligations under such Development Plan (including the cost to GW Pharma of relevant clinical trial insurance) other than the costs to GW Pharma of generating the <strong>CMC Data</strong> (\u201cDevelopment Costs\u201d).", "Promptly after the Effective Date, Biocon shall provide to Equillium true and complete copies of Biocon\u2019s updated Investigator\u2019s Brochure for all available CHO-derived ITO formulations and related supporting materials, and all preclinical, toxicology and <strong>CMC Data</strong> existing as of the Effective Date for all available CHO-derived ITO formulations; in each case, at Biocon\u2019s sole expense, subject to Section 4.2(a)(iii).", "The Parties agree that Otsuka shall have no right to exercise its license right granted under Section 2.1 to use the Manufacturing GW Pharma Know-How or GW Pharma <strong>CMC Data</strong> to make and have made Licensed Products or BDS unless and until it is permitted to do so under the terms of the Manufacturing and Supply Agreement.", "All activities carried out in relation to any Development Plan (other than generation of the <strong>CMC Data</strong>) will be financed by Otsuka including all activities to be managed and conducted by GW Pharma in accordance with such Development Plan.", "Each Party shall use the Safety and <strong>CMC Data</strong> provided to it pursuant to this Section 2.4.3(b) solely to Develop and Commercialize the Co-Co Candidate, Co-Co Products and Co-Co Diagnostic Products in the Field in the Territory (in the case of Celgene), and in the United States in the Field (in the case of Jounce).", "Each Party shall use the Safety and <strong>CMC Data</strong> provided to it pursuant to this Section 2.3.3(b) solely to Develop and Commercialize Licensed Products in the Field in the ROW Territory (in the case of Celgene), and in the Field outside the ROW Territory (in the case of Juno).", "Without limitation of Section 3.1, Gilead, under the oversight of the JDC, shall have primary responsibility for formulation and Manufacturing Process development for, and preparation of the <strong>CMC Data</strong> relating to, the Combination Product as contemplated by the Development Plan.", "Upon Licensee\u2019s reasonable request, AstraZeneca shall provide Licensee one or more letters permitting Licensee to reference the <strong>CMC Data</strong> for the Licensed Compound solely to the extent necessary for Licensee to prepare, submit, obtain or maintain an IND, Drug Approval Application, or other Regulatory Approval for a Licensed Product in the Field in the Territory."], "related": [["dxc-data", "DXC Data", "DXC Data"], ["genetic-data", "genetic data", "genetic data"], ["traffic-data", "traffic data", "traffic data"], ["biometric-data", "biometric data", "biometric data"], ["public-data", "Public data", "Public data"]], "related_snippets": [], "updated": "2025-12-01T05:47:12+00:00"}, "json": true, "cursor": ""}}